VJOncology is committed to improving our service to you

ASCO 2020 | RESILIENT: liposomal irinotecan in relapsed SCLC

VJOncology is committed to improving our service to you

David R. Spigel

David R. Spigel, MD, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, discusses the ongoing phase III RESILIENT study (NCT03088813) which aims to evaluate the efficacy of liposomal irinotecan against standard topotecan therapy in relapsed small cell lung cancer (SCLC) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter